Stock Analysis on Net

Danaher Corp. (NYSE:DHR)

Analysis of Liquidity Ratios

Microsoft Excel

Liquidity Ratios (Summary)

Danaher Corp., liquidity ratios

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Current ratio 1.68 1.89 1.43 1.86 5.19
Quick ratio 1.18 1.30 0.89 1.36 4.68
Cash ratio 0.71 0.71 0.32 0.82 4.04

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Danaher Corp. current ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Danaher Corp. quick ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Danaher Corp. cash ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023.

Current Ratio

Danaher Corp., current ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Current assets 13,937 15,883 11,648 13,802 25,597
Current liabilities 8,274 8,389 8,140 7,402 4,932
Liquidity Ratio
Current ratio1 1.68 1.89 1.43 1.86 5.19
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. 0.87 0.96 0.79 0.84 3.18
Amgen Inc. 1.65 1.41 1.59 1.81 1.44
Bristol-Myers Squibb Co. 1.43 1.25 1.52 1.58 1.60
Eli Lilly & Co. 0.94 1.05 1.23 1.40 1.16
Gilead Sciences Inc. 1.43 1.29 1.27 1.40 3.10
Johnson & Johnson 1.16 0.99 1.35 1.21 1.26
Merck & Co. Inc. 1.25 1.47 1.27 1.02 1.24
Moderna Inc. 3.42 2.73 1.76 1.43 7.89
Pfizer Inc. 0.91 1.22 1.40 1.35 0.88
Regeneron Pharmaceuticals Inc. 5.69 5.06 3.56 3.63 3.67
Thermo Fisher Scientific Inc. 1.75 1.48 1.50 2.13 1.92
Current Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 1.26 1.29 1.35 1.35 1.66
Current Ratio, Industry
Health Care 1.14 1.16 1.21 1.21 1.34

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Current ratio = Current assets ÷ Current liabilities
= 13,937 ÷ 8,274 = 1.68

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Danaher Corp. current ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023.

Quick Ratio

Danaher Corp., quick ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Cash and equivalents 5,864 5,995 2,586 6,035 19,912
Trade accounts receivable, less allowance for doubtful accounts 3,922 4,918 4,631 4,045 3,191
Total quick assets 9,786 10,913 7,217 10,080 23,104
 
Current liabilities 8,274 8,389 8,140 7,402 4,932
Liquidity Ratio
Quick ratio1 1.18 1.30 0.89 1.36 4.68
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. 0.63 0.69 0.56 0.60 2.91
Amgen Inc. 0.99 0.95 1.06 1.30 1.01
Bristol-Myers Squibb Co. 1.04 0.87 1.20 1.28 1.26
Eli Lilly & Co. 0.52 0.63 0.80 0.85 0.68
Gilead Sciences Inc. 1.06 0.99 0.95 1.08 2.86
Johnson & Johnson 0.82 0.71 1.04 0.91 0.94
Merck & Co. Inc. 0.68 0.93 0.73 0.58 0.78
Moderna Inc. 3.15 2.29 1.52 1.37 7.74
Pfizer Inc. 0.50 0.80 1.00 0.78 0.50
Regeneron Pharmaceuticals Inc. 4.82 4.16 2.98 2.86 2.81
Thermo Fisher Scientific Inc. 1.27 1.06 1.00 1.63 1.19
Quick Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.84 0.90 0.97 0.96 1.27
Quick Ratio, Industry
Health Care 0.83 0.86 0.90 0.90 1.00

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 9,786 ÷ 8,274 = 1.18

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Danaher Corp. quick ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023.

Cash Ratio

Danaher Corp., cash ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Cash and equivalents 5,864 5,995 2,586 6,035 19,912
Total cash assets 5,864 5,995 2,586 6,035 19,912
 
Current liabilities 8,274 8,389 8,140 7,402 4,932
Liquidity Ratio
Cash ratio1 0.71 0.71 0.32 0.82 4.04
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. 0.34 0.31 0.28 0.30 2.56
Amgen Inc. 0.60 0.59 0.66 0.91 0.69
Bristol-Myers Squibb Co. 0.55 0.42 0.78 0.83 0.84
Eli Lilly & Co. 0.11 0.13 0.26 0.29 0.21
Gilead Sciences Inc. 0.64 0.57 0.56 0.65 2.50
Johnson & Johnson 0.50 0.42 0.70 0.59 0.54
Merck & Co. Inc. 0.28 0.54 0.34 0.30 0.47
Moderna Inc. 2.85 2.01 1.18 1.05 7.71
Pfizer Inc. 0.27 0.54 0.73 0.47 0.26
Regeneron Pharmaceuticals Inc. 3.17 2.46 1.45 1.33 1.53
Thermo Fisher Scientific Inc. 0.58 0.50 0.33 1.00 0.39
Cash Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.46 0.51 0.58 0.57 0.89
Cash Ratio, Industry
Health Care 0.44 0.48 0.52 0.53 0.64

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 5,864 ÷ 8,274 = 0.71

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Danaher Corp. cash ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023.